Biotechnology company running clinical operations, researching, developing and delivering psychedelic medicines to treat addictions Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) announced having submitted a patent application for a new chemical class of Entactogen-like molecules to treat a range of addictions.
The addictions include; substance use addiction such as alcohol, behavioral addictions like gambling disorder and compulsive sexual behavior. This patent filing will strengthen the company’s intellectual property portfolio and pipeline for treatment of a wider range of addictions.
This new chemical series, presents a significant step forward towards development of entactogens and provides a key milestone in Awakn’s drug discovery R&D activities. This patent application also strengthens the company’s position as a global leader in the psychedelic biotechnology industry.
“Our ambition is to fully integrate effective psychedelic-based treatment into mainstream healthcare to better treat addiction. We are fortunate to have many of the world’s leading researchers and drug discovery experts supporting and delivering our vision at Awakn. Our clinical team has unparalleled experience in treating addiction, and now with the development of a new entactogen series and a world-class entactogen discovery pipeline, Awakn’s place as a global leader in this space is strengthened,” said the company’s CEO, Anthony Tennyson.
Back in October, Awakn said it would advance the NCE program in lead optimization with its research partner Evotec. The new Entactogen-like molecules which the patent has been filed for, will play an important role in this research with an aim to multiple compounds and progress them into clinical development.
